Rhupus Syndrome and Efficacy of Etanercept Treatment

the First People's Hospital of Chenzhou

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02766439

Enrollment

Registered

2016-05-09

Start date

2013-03-31

Completion date

2015-03-31

Last updated

2016-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhupus Syndrome, Etanercept

Brief summary

between March 2013 and March 2014, Rhupus patients were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

Detailed description

between March 2013 and March 2014, patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) \>5.1 were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

Interventions

DRUGetanercept

25-mg etanercept injection subcutaneously twice a week

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

\- Rhupus patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) \>5.1

Exclusion criteria

\- those who had participated in other studies

Design outcomes

Primary

Measure	Time frame
Disease Activity Score in 28 Joints (DAS28)	24 week

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026